ArticleJACC. Asia2023

Tafolecimab, A Novel Member of PCSK9 Monoclonal Antibodies, Is Worth Expecting in a Chinese Population.

Jian-Jun LiPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.